Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19212523 | KNEE ARTHROPLASTY METHOD | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19091700 | LIQUID LEVEL AND FLOW RATE DETECTION WITHIN A CELL PROCESSING SYSTEM | March 2025 | October 2025 | Allow | 7 | 1 | 0 | No | No |
| 19089212 | HEALTH RISK MONITORING METHOD AND APPARATUS FOR SUBSURFACE SOIL POLLUTION OF IMPERVIOUS SURFACE IN URBAN FACTORIES | March 2025 | November 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18975926 | APPARATUS AND METHOD FOR AUTOMATICALLY VALIDATING QUALITY DATA ASSOCIATED WITH AT LEAST A SLIDE | December 2024 | September 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18946698 | METHODS OF PREDICTING DOPAMINE PRODUCTION CAPABILITY OF DIFFERENTIATED NEURONAL CELLS | November 2024 | February 2026 | Allow | 15 | 3 | 1 | No | No |
| 18828382 | SYSTEM AND METHOD FOR ANALYZING SPECTRAL DATA USING ARTIFICIAL INTELLIGENCE | September 2024 | September 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18671152 | ARTIFICIAL INTELLIGENCE BASED SYSTEMS AND METHODS FOR ANALYZING MICRO-RIBONUCLEIC ACID (miRNA) SIGNATURE SEQUENCES AND PROFILES IN BIOLOGICAL SAMPLES | May 2024 | October 2025 | Abandon | 17 | 2 | 1 | Yes | Yes |
| 18625009 | PREDICTING PERSISTENCE OR REDUCTION IN USER INTERACTIONS ACROSS SESSIONS USING MACHINE LEARNING MODELS AND EVENT DATA | April 2024 | November 2025 | Allow | 19 | 4 | 1 | Yes | No |
| 18407997 | CHEMICAL COMPUTATION GRAPHS | January 2024 | November 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18500890 | MICROSATELLITE INSTABILITY DETECTION IN CELL-FREE DNA | November 2023 | February 2025 | Allow | 16 | 2 | 1 | No | No |
| 18385999 | ASSAY AND RELATED METHODS, KITS AND DEVICES | November 2023 | December 2025 | Abandon | 25 | 4 | 1 | Yes | No |
| 18463912 | METHOD AND APPARATUS FOR PROVIDING INFORMATION ASSOCIATED WITH IMMUNE PHENOTYPES FOR PATHOLOGY SLIDE IMAGE | September 2023 | February 2026 | Allow | 29 | 5 | 1 | Yes | No |
| 18171360 | METHOD FOR DIAGNOSING CANCER AND PREDICTING CANCER TYPE BY USING TERMINAL SEQUENCE MOTIF FREQUENCY AND SIZE OF CELL-FREE NUCLEIC ACID FRAGMENT | February 2023 | June 2025 | Allow | 28 | 4 | 1 | Yes | No |
| 18169750 | METHOD FOR DIAGNOSING CANCER AND PREDICTING TYPE OF CANCER BASED ON SINGLE NUCLEOTIDE VARIANT IN CELL-FREE DNA | February 2023 | April 2025 | Allow | 26 | 3 | 1 | Yes | No |
| 18163138 | METHODS AND SYSTEMS FOR DETECTING COLORECTAL CANCER VIA NUCLEIC ACID METHYLATION ANALYSIS | February 2023 | May 2025 | Allow | 28 | 4 | 1 | Yes | No |
| 17864559 | SYSTEMS AND METHODS FOR PROCESSING ELECTRONIC IMAGES TO DETERMINE FLOW USING FLOW RATIO | July 2022 | March 2026 | Allow | 44 | 1 | 0 | No | No |
| 17629638 | KINEMATIC DATA PROCESSING | January 2022 | February 2026 | Abandon | 48 | 1 | 0 | No | No |
| 17556434 | SYSTEMS AND METHODS FOR IDENTIFYING RARE CELLS | December 2021 | February 2025 | Allow | 38 | 1 | 2 | Yes | No |
| 17554749 | WIRELESS MONITORING OF HEMODIALYSIS TREATMENT DATA IN REAL-TIME VIA A BLOOD MONITOR NETWORK | December 2021 | December 2025 | Allow | 48 | 0 | 0 | No | No |
| 17530643 | DIRECTED EVOLUTION FOR MEMBRANE DEVELOPMENT IN THREE DIMENSIONS | November 2021 | November 2025 | Allow | 48 | 1 | 0 | Yes | No |
| 17504866 | Modified Hemofiltration Method for Clearing Peripheral ?-synuclein Aggregates in Patient with Neurodegenerative Disease | October 2021 | January 2026 | Allow | 51 | 1 | 0 | No | No |
| 17500312 | SYSTEM AND METHOD FOR MODELING THE STRUCTURE AND FUNCTION OF BIOLOGICAL SYSTEMS | October 2021 | January 2026 | Abandon | 51 | 1 | 0 | No | No |
| 17491014 | INTRAOPERATIVE ROD GENERATION BASED ON AUTO IMPLANT DETECTION | September 2021 | December 2025 | Allow | 50 | 1 | 0 | No | No |
| 17488792 | ASSESSMENT METHOD AND DEVICE FOR INFECTIOUS DISEASE TRANSMISSION, COMPUTER EQUIPMENT AND STORAGE MEDIUM | September 2021 | December 2025 | Allow | 51 | 1 | 1 | Yes | No |
| 17388595 | SYSTEMS AND METHODS FOR IMAGE PROCESSING TO DETERMINE BLOOD FLOW | July 2021 | November 2025 | Allow | 52 | 1 | 0 | No | No |
| 17376559 | SYSTEMS AND METHODS FOR TREATMENT PLANNING BASED ON PLAQUE PROGRESSION AND REGRESSION CURVES | July 2021 | August 2025 | Allow | 49 | 2 | 0 | Yes | No |
| 17367675 | SYSTEMS AND METHODS FOR IMAGE PROCESSING TO DETERMINE BLOOD FLOW | July 2021 | January 2026 | Allow | 55 | 2 | 0 | Yes | No |
| 17332480 | Dynamic Adaptation System for Surgical Simulation | May 2021 | January 2026 | Allow | 56 | 2 | 1 | No | No |
| 17325247 | SYSTEMS AND METHODS FOR USING GEOMETRY SENSITIVITY INFORMATION FOR GUIDING WORKFLOW | May 2021 | October 2025 | Allow | 53 | 1 | 0 | Yes | No |
| 17315977 | SYSTEMS AND METHODS OF PROCESSING IMAGES TO DETERMINE PATIENT-SPECIFIC PLAQUE PROGRESSION BASED ON THE PROCESSED IMAGES | May 2021 | April 2025 | Allow | 47 | 1 | 0 | Yes | No |
| 17243066 | Methods for Modeling Hepatic Inflammation | April 2021 | December 2025 | Allow | 56 | 2 | 0 | Yes | No |
| 17237730 | METHOD, APPARATUS AND SYSTEM FOR TESTING BLOOD | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17237144 | SYSTEMS AND METHODS FOR SIMULATION OF OCCLUDED ARTERIES AND OPTIMIZATION OF OCCLUSION-BASED TREATMENTS | April 2021 | April 2025 | Allow | 48 | 1 | 0 | No | No |
| 17201589 | SYSTEMS AND METHODS FOR VESSEL REACTIVITY TO GUIDE DIAGNOSIS OR TREATMENT OF CARDIOVASCULAR DISEASE | March 2021 | April 2025 | Allow | 49 | 1 | 0 | No | No |
| 17198822 | METHOD FOR PREDICTING DISEASE STATE, THERAPEUTIC RESPONSE, AND OUTCOMES BY SPATIAL BIOMARKERS | March 2021 | May 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17179298 | CANCER DETECTION METHODS | February 2021 | March 2026 | Allow | 60 | 1 | 1 | No | No |
| 17118766 | SYSTEM AND METHODS FOR OPTOGENETIC EVALUATION OF HUMAN NEUROMUSCULAR FUNCTION | December 2020 | July 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17095206 | SYSTEMS AND METHODS FOR USE OF KNOWN ALLELES IN READ MAPPING | November 2020 | May 2025 | Allow | 55 | 1 | 0 | No | No |
| 17079273 | CALIBRATION OF SIMULATED CARDIOGRAMS | October 2020 | August 2025 | Allow | 58 | 1 | 1 | No | No |
| 17037784 | SYSTEMS AND METHODS FOR TREATMENT PLANNING BASED ON PLAQUE PROGRESSION AND REGRESSION CURVES | September 2020 | July 2025 | Allow | 58 | 2 | 0 | No | No |
| 17029527 | METHODS FOR HAPLOTYPING SINGLE CELLS | September 2020 | July 2025 | Abandon | 57 | 1 | 0 | No | No |
| 16978518 | IMPROVEMENTS IN VARIANT DETECTION | September 2020 | March 2026 | Allow | 60 | 3 | 1 | No | No |
| 16965896 | ANALYTICAL SYSTEMS AND METHODS | July 2020 | November 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16920641 | TECHNIQUES FOR BIAS CORRECTION IN SEQUENCE DATA | July 2020 | September 2024 | Allow | 50 | 8 | 1 | Yes | No |
| 16898672 | SYSTEMS AND METHODS FOR CARDIOVASCULAR BLOOD FLOW AND MUSCULOSKELETAL MODELING FOR PREDICTING DEVICE FAILURE OR CLINICAL EVENTS | June 2020 | May 2025 | Allow | 59 | 1 | 1 | No | No |
| 16644636 | SCAFFOLDS, SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR REGENERATING A PULP | March 2020 | May 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16791523 | SYSTEMS AND METHODS FOR PREDICTING TISSUE VIABILITY DEFICITS FROM PHYSIOLOGICAL, ANATOMICAL, AND PATIENT CHARACTERISTICS | February 2020 | August 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16789901 | UNIFIED PLATFORM FOR MONITORING AND CONTROL OF BLOOD GLUCOSE LEVELS IN DIABETIC PATIENTS | February 2020 | February 2025 | Allow | 60 | 2 | 0 | Yes | No |
| 16691134 | SYSTEMS AND METHODS FOR TREATMENT PLANNING BASED ON PLAQUE PROGRESSION AND REGRESSION CURVES | November 2019 | February 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16595086 | Noise Rejection Methods and Apparatus for Sparsely Sampled Analyte Sensor Data | October 2019 | April 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16550672 | METHODS FOR DETECTING MUTATION LOAD FROM A TUMOR SAMPLE | August 2019 | August 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16426877 | SYSTEMS AND METHODS FOR PROCESSING ELECTRONIC IMAGES | May 2019 | September 2024 | Allow | 60 | 1 | 1 | No | No |
| 16397218 | SYSTEMS AND METHODS FOR SIMULATION OF HEMODIALYSIS ACCESS AND OPTIMIZATION | April 2019 | November 2024 | Abandon | 60 | 2 | 0 | No | No |
| 16396005 | DEVICE SPECIFIC FINITE ELEMENT MODELS FOR SIMULATING ENDOVASCULAR TREATMENT | April 2019 | October 2024 | Allow | 60 | 2 | 1 | No | No |
| 16380771 | SYSTEM AND METHOD FOR DETERMINING OPTIMIZED FOOD COMBINATIONS | April 2019 | January 2026 | Allow | 60 | 5 | 1 | Yes | No |
| 16291967 | SYSTEMS AND METHODS FOR PREDICTING PERFUSION DEFICITS FROM PHYSIOLOGICAL, ANATOMICAL, AND PATIENT CHARACTERISTICS | March 2019 | July 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16241573 | SYSTEMS AND METHODS FOR DETERMINATION OF BLOOD FLOW CHARACTERISTICS AND PATHOLOGIES THROUGH MODELING OF MYOCARDIAL BLOOD SUPPLY | January 2019 | August 2024 | Allow | 60 | 3 | 0 | Yes | No |
| 16056830 | INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF | August 2018 | May 2025 | Allow | 60 | 3 | 1 | No | No |
| 15922721 | SYSTEMS, DEVICES, AND/OR PROCESSES FOR OMIC AND/OR BEHAVIORAL CONTENT PROCESSING | March 2018 | July 2024 | Allow | 60 | 6 | 0 | Yes | No |
| 15756274 | Method of Determining Risk of an Adverse Cardiac Event | February 2018 | April 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 15715716 | METHOD FOR PREDICTING A DRUG RESPONSE BASED ON THE ATTRACTOR DYNAMICS OF THE NETWORK OF A CANCER-CELL AND DEVICE FOR THE SAME | September 2017 | August 2025 | Abandon | 60 | 8 | 1 | No | Yes |
| 15524181 | BIOPHYSICAL PLATFORM FOR DRUG DEVELOPMENT BASED ON ENERGY LANDSCAPE | May 2017 | July 2024 | Allow | 60 | 4 | 1 | Yes | Yes |
| 15443102 | METHODS AND APPARATUSES FOR PREDICTING RISK OF PROSTATE CANCER AND PROSTATE GLAND VOLUME | February 2017 | June 2024 | Allow | 60 | 10 | 1 | Yes | No |
| 14201758 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | March 2014 | May 2017 | Allow | 39 | 1 | 0 | No | No |
| 13692859 | STRUCTURAL MODEL OF G PROTEIN-COUPLED RECEPTOR AND METHOD FOR DESIGNING LIGAND CAPABLE OF BINDING TO G PROTEIN-COUPLED RECEPTOR USING THE STRUCTURAL MODEL | December 2012 | February 2015 | Allow | 27 | 2 | 0 | Yes | No |
| 13568738 | METHOD AND SYSTEM FOR COMPARATIVE GENOMICS | August 2012 | January 2014 | Allow | 17 | 2 | 0 | No | No |
| 13306774 | MOLECULAR MOTOR | November 2011 | January 2014 | Allow | 25 | 1 | 1 | No | No |
| 13304962 | METHOD AND SYSTEM FOR ANALYZING CALCIUM TRANSIENTS IN COUPLED CELLS | November 2011 | November 2013 | Allow | 33 | 2 | 1 | Yes | No |
| 13285687 | METHODS FOR ANALYZING HIGH DIMENSIONAL DATA FOR CLASSIFYING, DIAGNOSING, PROGNOSTICATING, AND/OR PREDICTING DISEASES AND OTHER BIOLOGICAL STATES | October 2011 | August 2013 | Allow | 22 | 3 | 0 | No | No |
| 12994723 | MODELS FOR COMBINATORIAL PERTURBATIONS OF LIVING BIOLOGICAL SYSTEMS | June 2011 | July 2013 | Allow | 32 | 2 | 1 | Yes | No |
| 13037851 | SUPERVISED PRINCIPAL COMPONENT ANALYSIS | March 2011 | November 2012 | Allow | 21 | 1 | 1 | No | No |
| 13018195 | TEMPLATE CONSTRAINED FRAGMENT ALIGNMENT USED TO IDENTIFY FRAGMENTS OF SIMILAR SHAPE AND ACTIVITY IN DRUG DEVELOPMENT | January 2011 | April 2013 | Allow | 26 | 1 | 0 | No | No |
| 12933936 | METHODS AND GENE EXPRESSION SIGNATURE FOR ASSESSING GROWTH FACTOR SIGNALING PATHWAY REGULATION STATUS | September 2010 | October 2012 | Allow | 25 | 1 | 1 | No | No |
| 12858674 | METHODS FOR ANALYZING HIGH DIMENSIONAL DATA FOR CLASSIFYING, DIAGNOSING, PROGNOSTICATING, AND/OR PREDICTING DISEASES AND OTHER BIOLOGICAL STATES | August 2010 | July 2011 | Allow | 10 | 1 | 1 | No | No |
| 12837452 | METHODS AND SYSTEMS FOR PROCESSING GENOMIC DATA | July 2010 | November 2012 | Allow | 28 | 1 | 1 | No | No |
| 12744363 | Novel Disease Treatment by Predicting Drug Association | May 2010 | September 2013 | Allow | 40 | 4 | 0 | No | No |
| 12721968 | THERAPEUTIC IMPLICATIONS OF DICKKOPF AFFECTING CANCER STEM CELL FATE | March 2010 | February 2014 | Allow | 47 | 2 | 1 | Yes | No |
| 12686311 | METHODS AND SYSTEMS FOR CHARACTERIZING A CELLULAR CONSTITUENT USING RESPONSE PROFILES | January 2010 | November 2012 | Allow | 35 | 2 | 1 | No | No |
| 12686359 | LASER MEDIATED SECTIONING AND TRANSFER OF CELL COLONIES | January 2010 | March 2014 | Allow | 50 | 3 | 1 | Yes | No |
| 12643933 | METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POLYMORPHIC GENETIC MARKERS | December 2009 | March 2012 | Allow | 27 | 3 | 0 | Yes | No |
| 12632221 | CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME | December 2009 | April 2011 | Allow | 17 | 2 | 0 | No | No |
| 12621175 | TECHNIQUES FOR PURPOSING A NEW COMPOUND AND FOR RE-PURPOSING A DRUG | November 2009 | March 2013 | Allow | 40 | 1 | 1 | Yes | No |
| 12574195 | CHARACTERIZATION OF PHENOTYPES BY GENE EXPRESSION PATTERNS AND CLASSIFICATION OF SAMPLES BASED THEREON | October 2009 | August 2010 | Allow | 10 | 1 | 0 | No | No |
| 12571888 | METHOD AND APPARATUS FOR CHEMICAL GENETIC PROGRAMMING | October 2009 | September 2011 | Allow | 24 | 1 | 0 | No | No |
| 12551485 | CONCURRENT TWO-PHASE COMPLETION GENETIC ALGORITHM MULTI-PROCESSOR INSTANCE SYSTEM | August 2009 | August 2011 | Abandon | 23 | 1 | 0 | Yes | No |
| 12551478 | CONCURRENT TWO-PHASE COMPLETION GENETIC ALGORITHM SYSTEM AND METHODS | August 2009 | August 2011 | Abandon | 23 | 1 | 0 | Yes | No |
| 12477596 | VISUAL-SERVOING OPTICAL MICROSCOPY | June 2009 | March 2011 | Allow | 22 | 2 | 0 | No | No |
| 12308916 | A METHOD OF GENERATING AN IDENTIFICATION ELEMENT | December 2008 | September 2012 | Allow | 45 | 2 | 1 | Yes | No |
| 12248738 | SYSTEMS AND METHODS USING INDUCED PERTURBATION TO DETERMINE PHYSIOLOGICAL PARAMETERS | October 2008 | April 2013 | Allow | 54 | 2 | 1 | No | No |
| 12233996 | METABOLIC PHENOTYPING | September 2008 | April 2013 | Allow | 55 | 5 | 1 | Yes | No |
| 12020171 | APPARATUS AND METHODS FOR EARLY STAGE PERITONITIS DETECTION AND FOR IN VIVO TESTING OF BODILY FLUID | January 2008 | February 2014 | Allow | 60 | 4 | 0 | Yes | No |
| 11987415 | HEPATIC DISEASE-EVALUATING APPARATUS, HEPATIC DISEASE-EVALUATING METHOD, HEPATIC DISEASE-EVALUATING SYSTEM, HEPATIC DISEASE-EVALUATING PROGRAM AND RECORDING MEDIUM | November 2007 | August 2011 | Allow | 45 | 2 | 0 | No | No |
| 11942022 | METHOD FOR RECONSTRUCTING EVOLUTIONARY DATA | November 2007 | September 2013 | Allow | 60 | 3 | 0 | No | No |
| 11930108 | SECONDARY STRUCTURE DEFINING DATABASE AND METHODS FOR DETERMINING IDENTITY AND GEOGRAPHIC ORIGIN OF AN UNKNOWN BIOAGENT THEREBY | October 2007 | March 2012 | Allow | 53 | 3 | 0 | Yes | No |
| 11929910 | SYSTEMS FOR RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND ANIMALS | October 2007 | February 2012 | Allow | 52 | 4 | 1 | No | No |
| 11928901 | METHODS FOR ANALYZING HIGH DIMENSION DATA FOR CLASSIFYING, DIAGNOSING, PROGNOSTICATING, AND/OR PREDICTING DISEASES AND OTHER BIOLOGICAL STATES | October 2007 | March 2010 | Allow | 29 | 3 | 0 | No | No |
| 11930017 | METHOD FOR RAPID DETECTION AND IDENTIFICATION OF BIOAGENTS | October 2007 | March 2012 | Allow | 52 | 2 | 1 | Yes | No |
| 11841338 | SYSTEM AND METHOD FOR MOLECULAR COMMUNICATION | August 2007 | November 2012 | Allow | 60 | 3 | 0 | Yes | No |
| 11840041 | HIGH THROUGHPUT FUNCTIONAL GENOMICS | August 2007 | January 2010 | Allow | 29 | 0 | 0 | No | No |
| 11805743 | SIMULATION SYSTEM OF FUNCTION OF BIOLOGICAL ORGAN | May 2007 | August 2011 | Allow | 51 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CLOW, LORI A.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 36.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CLOW, LORI A works in Art Unit 1687 and has examined 170 patent applications in our dataset. With an allowance rate of 92.4%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 53 months.
Examiner CLOW, LORI A's allowance rate of 92.4% places them in the 78% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CLOW, LORI A receive 3.12 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CLOW, LORI A is 53 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +4.8% benefit to allowance rate for applications examined by CLOW, LORI A. This interview benefit is in the 29% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 29.4% of applications are subsequently allowed. This success rate is in the 55% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 38.3% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 2% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 90.0% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 77.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 70.7% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 30.6% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.